Phenotypic and Functional Alterations in Tunneling Nanotubes Formed by Glaucomatous Trabecular Meshwork Cells.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 11 2019
Historique:
entrez: 2 11 2019
pubmed: 2 11 2019
medline: 1 2 2020
Statut: ppublish

Résumé

Trabecular meshwork (TM) cells detect and coordinate responses to intraocular pressure (IOP) in the eye. TM cells become dysfunctional in glaucoma where IOP is often elevated. Recently, we showed that normal TM (NTM) cells communicate by forming tubular connections called tunneling nanotubes (TNTs). Here, we investigated TNTs in glaucomatous TM (GTM) cells. Primary GTM and NTM cells were established from cadaver eyes. Transfer of Vybrant DiO and DiD-labeled vesicles via TNT connections was measured. Imaris software measured the number and length of cell protrusions from immunofluorescent confocal images. Live-cell imaging of the actin cytoskeleton was performed. The distribution of myosin-X, a regulator of TNTs/filopodia, was investigated in TM cells and tissue. GTM cells contained significantly more transferred fluorescent vesicles than NTM cells (49.6% vs. 35%). Although NTM cells had more protrusions at the cell surface than GTM cells (7.61 vs. 4.65 protrusions/cell), GTM protrusions were significantly longer (12.1 μm vs. 9.76 μm). Live-cell imaging demonstrated that the GTM actin cytoskeleton was less dynamic, and vesicle transfer between cells was significantly slower than NTM cells. Furthermore, rearrangement of the actin cortex adjacent to the TNT may influence TNT formation. Myosin-X immunostaining was punctate and disorganized in GTM cells and tissue compared to age-matched NTM controls. Together, our data demonstrate that GTM cells have phenotypic and functional differences in their TNTs. Significantly slower vesicle transfer via TNTs in GTM cells may delay the timely propagation of cellular signals when pressures become elevated in glaucoma.

Identifiants

pubmed: 31675075
pii: 2754054
doi: 10.1167/iovs.19-28084
pmc: PMC6827425
doi:

Substances chimiques

MYO10 protein, human 0
Myosins EC 3.6.4.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4583-4595

Subventions

Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019643
Pays : United States

Références

Sci Rep. 2013;3:1365
pubmed: 23455567
J Biol Chem. 2010 Mar 26;285(13):9506-15
pubmed: 20081229
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
Exp Gerontol. 2005 Aug-Sep;40(8-9):745-8
pubmed: 16051457
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5353-65
pubmed: 18641286
Exp Cell Res. 2008 Dec 10;314(20):3669-83
pubmed: 18845141
Nat Rev Mol Cell Biol. 2008 Jun;9(6):431-6
pubmed: 18431401
Front Physiol. 2012 Apr 10;3:72
pubmed: 22514537
Nat Methods. 2014 Jul;11(7):731-3
pubmed: 24859753
Cell Commun Signal. 2018 Nov 8;16(1):76
pubmed: 30409198
J Cell Sci. 2013 Oct 1;126(Pt 19):4424-35
pubmed: 23886947
Cell Death Differ. 2011 Apr;18(4):732-42
pubmed: 21113142
J Cell Sci. 2019 Feb 11;132(3):
pubmed: 30659112
J Cell Physiol. 2019 Feb;234(2):1130-1146
pubmed: 30206931
Lancet. 2011 Apr 16;377(9774):1367-77
pubmed: 21453963
Invest Ophthalmol Vis Sci. 2012 May 04;53(5):2495-500
pubmed: 22562850
Biochim Biophys Acta. 2015 Mar;1852(3):379-85
pubmed: 25483712
Sci Rep. 2016 Feb 17;6:21315
pubmed: 26883567
Science. 2004 Feb 13;303(5660):1007-10
pubmed: 14963329
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1255-63
pubmed: 18952927
Br J Cancer. 2014 Jul 29;111(3):539-50
pubmed: 24921915
Acta Biomater. 2018 Apr 15;71:444-459
pubmed: 29524673
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1288-1295
pubmed: 28241317
J Biol Chem. 2010 Jun 18;285(25):19605-14
pubmed: 20392702
Curr Protoc Cell Biol. 2015 Jun 01;67:12.10.1-21
pubmed: 26061240
Prog Retin Eye Res. 2013 Nov;37:1-12
pubmed: 23770081
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):843-851
pubmed: 30807639
Sci Rep. 2017 Aug 17;7(1):8547
pubmed: 28819224
J Cell Biochem. 2013 Jun;114(6):1238-47
pubmed: 23129562
Exp Eye Res. 2008 Feb;86(2):271-81
pubmed: 18155193
Sci Rep. 2016 Dec 23;6:39632
pubmed: 28008977
Exp Eye Res. 2015 Apr;133:112-25
pubmed: 25819459
J Cell Sci. 2005 May 15;118(Pt 10):2079-82
pubmed: 15890982
Cell Mol Life Sci. 2016 Dec;73(23):4531-4545
pubmed: 27125884
Nat Cell Biol. 2002 Mar;4(3):246-50
pubmed: 11854753
Nat Cell Biol. 2009 Mar;11(3):328-36
pubmed: 19198598
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12411-6
pubmed: 16894163
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):94-101
pubmed: 24401029
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5298-5307
pubmed: 29049733
Microvasc Res. 2014 Mar;92:10-8
pubmed: 24486322
Mech Dev. 2013 Jun-Aug;130(6-8):381-7
pubmed: 23246917
Sci Rep. 2017 Oct 20;7(1):13685
pubmed: 29057977
J Cell Sci. 2000 Oct;113 Pt 19:3439-51
pubmed: 10984435
Curr Biol. 2014 Jul 21;24(14):1628-1635
pubmed: 25017211
J Glaucoma. 1995 Jun;4(3):183-8
pubmed: 19920666
Front Immunol. 2018 Jan 25;9:43
pubmed: 29422895
Acta Histochem Cytochem. 2007 Aug 30;40(4):101-11
pubmed: 17898874
Nat Med. 2012 Apr 15;18(5):759-65
pubmed: 22504485
Nat Cell Biol. 2009 Dec;11(12):1427-32
pubmed: 19935652
Nat Cell Biol. 2008 Feb;10(2):211-9
pubmed: 18193035
J Cell Sci. 2013 Feb 1;126(Pt 3):767-77
pubmed: 23239025
Chem Biol. 2013 May 23;20(5):701-12
pubmed: 23623350
J Cell Sci. 2018 Jul 19;131(14):
pubmed: 30026344
Exp Eye Res. 2009 Apr;88(4):713-7
pubmed: 18793636
Exp Eye Res. 2007 Feb;84(2):275-84
pubmed: 17126833
J Cell Sci. 2011 Nov 15;124(Pt 22):3733-41
pubmed: 22124140
J Immunol. 2006 Dec 15;177(12):8476-83
pubmed: 17142745
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37
pubmed: 11274082

Auteurs

Ying Ying Sun (YY)

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.

John M Bradley (JM)

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.

Kate E Keller (KE)

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH